|Report Code: PP10189||Report Type: Molecule-Type Pipeline Reports||Available format:|
Probiotics are live microorganisms that produces beneficial effects in human gut. Probiotics can be taken as a dietary supplement. They prevent diarrhoea and help to reduce the symptoms of irritable bowel syndrome. Probiotics comprise of a variety of microorganisms belonging to the Lactobacillus and Bifidobacterium groups. The only yeast probiotic that has proven to be effective is Saccharomyces boulardii. According to researchers, probiotics are effective in treatment of digestive disorders, allergic disorders, oral disorders, colic, common cold, and liver diseases. Lactobacillus plantarum W1 is a probiotic that reduces the excess cholesterol levels, stimulate TH1 cells, and restore the intestinal permeability of human gut.
Swecure AB is developing probiotics for the treatment of allergic disorders. Oragenics Inc. and Intrexon Corporation are developing ActoBiotic for the treatment of oral diseases. Some of the companies having probiotics pipeline are NutraHelix Biotech Pvt Ltd. and Winclove Probiotics B.V.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.